PubMed · 2014 · 17 citations · 24 references
MedicineNephrologyPharmacologyInflammationRenal PathologyRenal PathophysiologyNephrotoxicity MechanismsRenal DiseaseRenal InflammationRenal Ischemic InjuryRenal PharmacologyRenal ToxicityAcute Kidney Injury PathophysiologyDrug-induced Acute Kidney InjuryInflammation In Renal InjuryInflammation In Renal ToxicityInflammation-mediated Tissue DamageNephrotoxic Kidney InjuryRenal Inflammatory Injury
OBJECTIVE: We investigate kidney injury caused by high dose bevacizumab to uncover the possible mechanisms involving in this process. METHODS: Forty rats were divided into four groups: cisplation group (treated with 1 mg/kg cisplation), Bev-high group (treated with 5 mg/kg bevacizumab); Bev-low group (treated with 2.5 mg/kg bevacizumab) and control group (treated with saline). The urine microalbumin, serum cystatin C, blood urea nitrogen and serum creatinine were detected in the four group rats, respectively. The immunoglobulin of IgG, IgA and IgM and protein of VEGF (vascular endothelial growth factor) and nephrin were detected by immunohistochemical methods. RESULTS: All the levels of microalbumin, cystatin C, serum creatinine and blood urea nitrogen in Bev-high group were significantly higher than those in normal control group (P < 0.05). The cystatin C was much more increased in kidney Bev-high group than cisplatin and Bev-low groups (P < 0.05). The light microscope showed a normal glomerular morphology in the four groups, while the electronic microscopy showed the podocytes were extensively fused in cisplatin group and Bev-high group. The two groups were found IgG and IgM deposition as well. The VEGF in kidney amples were down regulated in high dose bevacizumab group, whereas the nephrin and IgA showed no significant expression changes at all. CONCLUSION: Bevacizumab increases the risk of injury in glomerular filtration barrier in a dose dependent model. The injury may not only associate with the rising level of proteinuria but also with podocyte-dependent membrane structures.
24
K. Jin Kim, Bing Li, Jane Winer et al. · Nature · 1993 · 3.6K citations
Medicine, Cancer Biology, Oncology +14
VEGF Inhibition and Renal Thrombotic Microangiopathy
Vera Eremina, J. Ashley Jefferson, Jolanta Kowalewska et al. · New England Journal of Medicine · 2008 · 1.5K citations · Full text
Early detection of acute renal failure by serum cystatin C
Stefan Herget‐Rosenthal, G. Marggraf, Johannes Hüsing et al. · Kidney International · 2004 · 892 citations
FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme
Martin H. Cohen, Yuan Li Shen, Patricia Keegan et al. · The Oncologist · 2009 · 648 citations · Full text
Medicine, Oncology, Pharmacology +12